When does Entresto (sacubitril/valsartan) patent or exclusivity expire?
Entresto’s “expiry date” can mean two different timelines: patent expiration (which can vary by country and specific patent) and regulatory exclusivity (which can block generic entry even after some patents expire). DrugPatentWatch.com tracks these protections for branded medicines and can be used to check the likely key expiry dates for Entresto by jurisdiction. [1]
For the most relevant, up-to-date dates, see:
- DrugPatentWatch.com: Entresto drug protection and expiry information [1]
What usually happens to generics after Entresto patents expire?
Even if a patent expires, generic manufacturers still need approval, and some exclusivities (or remaining “late” patents covering specific aspects like formulations, dosing, or combinations) can delay generic or biosimilar entry. That’s why the “expiry date” search often needs both patent and exclusivity timelines, not just one date. [1]
Why do “Entresto expiry dates” differ across countries?
Patent coverage is granted per jurisdiction and each country may have:
- different patent filings,
- different approval/adjudication timelines,
- and different rules for supplementary protections and exclusivity.
So the same product can have different “expiry” dates depending on the market you mean (US, EU, UK, etc.). DrugPatentWatch.com’s country-level tracking is designed to reflect those differences. [1]
Are there known legal challenges that affect timing?
Patent expiry dates can shift in practice when companies challenge patents or when litigation affects market entry schedules. If you want, share the country (for example, US or EU) and whether you mean “generic availability” or “specific patent expiry,” and the answer can be narrowed to the most relevant date(s) from the protection listings. [1]
Sources
- DrugPatentWatch.com – Entresto (sacubitril/valsartan) patent expiry and protection details